Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART

NCT01683656 is registered in ClinicalTrials.gov with Calmy Alexandra as lead sponsor.

NCT NCT01683656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01683656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART
Lead sponsor
Calmy Alexandra
Phase
Phase 4
Overall status
Terminated
Start date
August 31, 2012
Completion date
July 31, 2014
Enrollment
4 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, hiv